Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Severe Acute Respiratory Syndrome 1 Mastocytosis 1 Lymphoma 1 Hypersensitivity 1 Hematopoietic and Lymphatic System Neoplasm 1 COVID-19 1

Interventions

Cyclophosphamide 62 Rituximab 51 fludarabine 34 Prednisone 34 Doxorubicin 29 Vincristine 26 Biopsy 26 Specimen Handling 22 Magnetic Resonance Spectroscopy 20 Bendamustine Hydrochloride 19 pembrolizumab 17 Lenalidomide 16 obinutuzumab 14 fludarabine phosphate 14 Etoposide 14 venetoclax 13 Tacrolimus 11 Mycophenolic Acid 10 Melphalan 10 Dexamethasone 10 zanubrutinib 9 ibrutinib 9 acalabrutinib 9 Radiotherapy 9 Gemcitabine 9 Cytarabine 9 Busulfan 9 Whole-Body Irradiation 8 Mesna 8 Filgrastim 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × BNT162 Vaccine × 1 year × Clear all

NCT05170399 2026-02-05

Vaccine Responses in Patients With B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 4 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡